Loading clinical trials...

Liver Cirrhosis Network Cohort Study | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

Liver Cirrhosis Network Cohort Study

NCT05740358•Northwestern University

Summary

Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants will have study visits every 6 months (180 days), with opportunities to complete specific visit components via telehealth or remotely. Visits will include collection of questionnaire data and the in-person visits will include questionnaires, physical exams, imaging, and sample collection.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age ≥ 18 years
•Willing to provide samples at baseline
•Cirrhosis
•Where Cirrhosis is defined as:
•1. At least one liver biopsy within 5 years prior to consent showing either: a) Metavir stage 4 fibrosis; Ishak Stage 5-6 fibrosis OR
•2. At least 2 of the following:
•1\. Evidence on imaging: Nodular liver with either splenomegaly or recanalized umbilical vein within the past year 2. Liver stiffness: VCTE within one year prior to consent or during Screening ≥12.5 kPa or MRE within one year prior to consent or during Screening ≥5 kPa 3. Evidence of varices demonstrated on imaging or endoscopy within 3 years prior to consent or during Screening 4. Either: FIB-4\>2.67 or platelets \<150/mL within 6 months prior to consent or during Screening 5. \>5 years METAVIR stage 4 fibrosis or Ishak stage 5-6

Exclusion Criteria

•Known and documented prior or current hepatocellular carcinoma (HCC) or cholangiocarcinoma
•Known transjugular intrahepatic portosystemic shunt (TIPS), balloon retrograde transvenous obliteration (BRTO) or porto-systemic shunt surgery regardless of time of occurrence
•Known prior solid organ transplant or bone marrow transplant
•Current participation in active medication treatment trials at the time of consent for LCN Cohort Study
•Prisoners or individuals with more than 180 days incarceration pending due to difficulty with visits
•Bariatric surgery in the last 180 days prior to consent
•Known history of fontan procedure-associated liver disease (FALD)
•Known current medical or psychiatric conditions which, in the opinion of the investigator, would make the participant unsuitable for the study or interfere with or prevent follow-up per protocol
•Current liver-unrelated end-stage organ failures (Dialysis, stage 3-4 congestive heart failure (CHF), current chronic obstructive pulmonary disease (COPD) on home oxygen, current known active malignancy besides non-melanomatous skin cancer or carcinoma in situ)
•Documented history of acute alcohol-associated hepatitis (according to NIAAA criteria as described in the MOP) in the 180 days prior to consent
+12 more criteria

Locations (14)

University of California San Diego NAFLD Research Center

La Jolla, California, United States

Keck Medical Center of USC

Los Angeles, California, United States

LAC + USC Medical Center

Los Angeles, California, United States

UCSF/Zuckerberg San Francisco General Hospital and Trauma Center

San Francisco, California, United States

UCSF Medical Center

San Francisco, California, United States

University of Miami Health System

Miami, Florida, United States

University of Michigan

Ann Arbor, Michigan, United States

Mayo Clinic

Rochester, Minnesota, United States

New York Presbyterian/Weill Cornell

New York, New York, United States

Columbia University Iriving School of Medicine

New York, New York, United States

Key Dates

Start Date

November 18, 2022

Primary Completion Date

October 24, 2030

Completion Date

October 24, 2030

Last Updated

January 13, 2026

Enrollment

1,222

ACTUAL participants

Conditions

CirrhosisCirrhosis, LiverCirrhosis EarlyCirrhosis Due to Hepatitis BCirrhosis AdvancedCirrhosis InfectiousCirrhosis AlcoholicCirrhosis, BiliaryCirrhosis CryptogenicCirrhosis Due to Hepatitis CCirrhosis Due to Primary Sclerosing CholangitisAutoimmune Hepatitis

EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis.

NCT05597488

Cirrhosis Portal

View study

RECRUITINGNA

Remote Electrical Stimulation for Pain and Depression Treatment in Cirrhosis

NCT06932783

Cirrhosis

View study

RECRUITING

Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 13, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Liver Cirrhosis Network Cohort Study

Inclusion Criteria

Exclusion Criteria

EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis.

Remote Electrical Stimulation for Pain and Depression Treatment in Cirrhosis

Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias

Mechanism of TIPS to Improve Sarcopenia

Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care

Verification of Risk Factors of Thrombohemorrhagic Complications in Recipients After Related Liver Transplantation